Results for this period
Interim period (second quarter)1 October 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The loss narrowed due to the recognition of revenue from a one-time technology transfer fee in the CDMO business, efforts to reduce the cost of sales, and decreases in research and development expenses and selling, general and administrative expenses. Increased gains on investment business partnerships also contributed to the reduction in the ordinary loss, while a ¥33 million valuation loss on investment securities was recorded as an extraordinary loss.
A description of events or conditions that may raise substantial doubt about the going concern assumption is provided. The company has continuously incurred operating losses and negative operating cash flow, creating a risk that may raise doubt about its ability to continue as a going concern; however, it has determined that no material uncertainty regarding the going concern assumption exists.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥414 million (YoY +2.3%) |
| Operating profit | ¥-629 million |
| Ordinary income | ¥-516 million |
| Profit attributable to owners of the parent | ¥-551 million |
| Net income per share | -¥2.06 |
| Equity ratio | End of the current fiscal period 89.4 / End of previous period 88.8 |
| Total assets | ¥3,987 million |
| Net assets | ¥3,574 million |
| Cash flows from operating activities | ¥-652,850 thousand |
| Cash flows from investing activities | ¥561,015 thousand |
| Cash flows from financing activities | ¥349,883 thousand |
| Cash and cash equivalents at end of period | ¥2,928,146 thousand |
| Full-year earnings forecast | Net Sales ¥943 million (YoY +16.4%) / Operating profit ¥-1,454 million / Ordinary income ¥-1,449 million / Net income ¥-1,453 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Cell Processing Business ¥413 million (YoY +2.3%), Regenerative Medicine Products Business ¥0 million (YoY +48.4%) |
| Segment profit | Cell Processing Business ¥-174 million, Regenerative Medicine Products Business ¥-177 million |
| Depreciation and amortization | ¥47,934 thousand |
| Impairment loss | ¥33,160 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income No / Extraordinary loss Impairment Loss on Investment Securities ¥33,160 thousand |
| Disclosure regarding the going concern assumption | A description of events or conditions that may raise substantial doubt about the going concern assumption is provided. The company has continuously incurred operating losses and negative operating cash flow, creating a risk that may raise doubt about its ability to continue as a going concern; however, it has determined that no material uncertainty regarding the going concern assumption exists. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 277,417,319 |
| Treasury Shares at Period-End | 64 |
| Factors Behind Changes in Business Performance | The loss narrowed due to the recognition of revenue from a one-time technology transfer fee in the CDMO business, efforts to reduce the cost of sales, and decreases in research and development expenses and selling, general and administrative expenses. Increased gains on investment business partnerships also contributed to the reduction in the ordinary loss, while a ¥33 million valuation loss on investment securities was recorded as an extraordinary loss. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The loss narrowed due to the recognition of a one-time technology transfer fee as revenue in the CDMO business, efforts to reduce the cost of sales, and decreases in research and development expenses and selling, general and administrative expenses. Increased gains on investment business partnerships also contributed to the reduction in the ordinary loss, while a ¥33 million valuation loss on investment securities was recorded as an extraordinary loss.